-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since the end of 2019, SARS-CoV-2, as a newly emerged pathogenic microorganism, has caused the pandemic of new coronary pneumonia
.
As of the end of November 2021, more than 257 million people worldwide have been infected with SARS-CoV-2, of which about 5.
New coronary pneumonia infection COVID-19 diabetes hypertensive blood vessels
Recently, a research article was published in Metabolism-Clinical and Experimental, an authoritative journal in the field of metabolic diseases.
The researchers aimed to compare the impact of pre-admission antidiabetic drugs on in-hospital mortality in patients with type 2 diabetes and COVID-19
.
We systematically searched PubMed, EMBASE, Scopus and Web of Science databases for studies (excluding case reports and review articles) published up to 30 November 2021
.
The researchers excluded papers on the use of antidiabetic drugs during hospitalization
We included 61 studies (3,061,584 participants), which were rated as low risk of bias
.
OR (95% CI) indicated that some drugs against covid-19-related deaths, including metformin [0.
metformin
CONCLUSIONS : Metformin, GLP-1RA and SGLT-2i were associated with lower mortality in T2DM patients with COVID-19
.
DPP-4i and insulin are associated with increased mortality
Metformin, GLP-1RA, and SGLT-2i were associated with lower mortality in patients with type 2 diabetes with COVID-19
Original source:
Nam Nhat Nguyen.
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta- analysis